TipRanks
Alnylam Pharmaceuticals (CH:DUL)
:DUL
Switzerland Market
DUL
Alnylam Pharma
RESEARCH TOOLSreports

Alnylam Pharma (DUL) Stock News & Sentiment

0 Followers
Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names
Premium
Market News
Overvalued Healthcare Stocks? Analysts See Upside in These 3 High P/E Names
13d ago
ALNY
BTSG
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
Premium
Ratings
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
13d ago
ALNY
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
Premium
Ratings
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
19d ago
ALNY
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
Premium
Ratings
Alnylam’s Emerging TTR Leadership Reinforces Buy Rating with Unchanged $455 Price Target
29d ago
ALNY
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
Premium
Ratings
Whitney Ijem Reiterates Buy on Alnylam, Keeps Price Target Unchanged at $429 Following CARDIO‑TTRansform Data
1M ago
ALNY
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
Premium
Ratings
Alnylam Upgraded to Buy on Strong ATTR Cardiomyopathy Positioning and Amvuttra Mega-Blockbuster Potential
1M ago
ALNY
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
Premium
Ratings
Alnylam Maintained at Buy as Analyst Reaffirms $346 Price Target on TTR Franchise Strength and Amvuttra Growth Visibility
1M ago
ALNY
More CH:DUL News >

DUL News on the Web

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Revvity (RVTY)
TipRanks News
Bullish
Alnylam Stock Stumbles as Hot Streak Cools
TipRanks News
Neutral
Alnylam Pharmaceuticals, Inc. RNAi Roundtable Call Transcript
GuruFocus News
Neutral
Analyst Maintains Buy Rating on Alnylam, Reiterates $357 Price Target on Long-Term Zilebesiran Opportunity
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Scholar Rock Holding (SRRK)
TipRanks News
Bullish
Alnylam Pharmaceuticals, Inc. at Morgan Stanley Global Healthcare Conference Transcript
GuruFocus News
Neutral
Hold Rating Reaffirmed as TTR Outlook Moderates; $300 Price Target Maintained
TipRanks News
Neutral
Here’s Why Alnylam Pharmaceuticals (ALNY) Declined
Insider Monkey
Bearish

News Score - Last 7 Days

Very Positive
CH:DUL
Sector Average
Media Buzz
This Week6 articles
Weekly Average8.75 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CH:DUL’s Media Buzz Sentiment?
6 articles about CH:DUL were published this week. In an average week, 8.75 articles are published.
    What is CH:DUL’s weekly average amount of articles?
    In an average week, 8.75 articles about CH:DUL are published.
      What is CH:DUL’s News Sentiment?
      100% of articles about CH:DUL were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        SMMTSummit Therapeutics
        CDNACareDx
        ARGXArgenx Se
        MEOBFMesoblast Limited
        KODKodiak Sciences
        Showing the stocks with the most bullish news sentiment over the past week